Does an ANA Test Take Longer if Positive?

A positive ANA (antinuclear antibody) test typically does take longer to process and report than a negative one. The reason is straightforward: when the initial screen comes back negative, the lab has its answer and can release the result. When the screen is positive, the sample usually triggers additional steps, including serial dilutions to determine the titer and, in many labs, further testing to identify the specific pattern or antibody involved. These extra steps can add anywhere from a few hours to several additional business days to your turnaround time, depending on the laboratory and the testing method used.

Why a Positive Screen Creates More Work

The most common method for ANA testing is indirect immunofluorescence, often abbreviated IIF. In this technique, your blood serum is placed on a slide containing cells, and a technician (or an automated reader) looks under a fluorescence microscope for a glow that indicates antibodies binding to the cell nuclei. If nothing lights up at the initial screening dilution, the result is negative, and the lab can move on. The whole read takes moments.

If the screen is positive, however, the lab needs to answer two follow-up questions: how strong is the reaction, and what pattern does it form? Answering the first question means performing serial dilutions. The lab dilutes your serum further and further, testing each dilution until the fluorescence disappears, to arrive at your titer. A result might come back as 1:80 (weakly positive) or 1:1280 (strongly positive), and each additional dilution step is another well on a slide that needs to be prepared, incubated, and read. Labs have noted that time and cost constraints push many of them to limit how many dilutions they actually perform, but a genuinely positive sample still requires more hands-on work than a negative one.

The second follow-up, pattern identification, adds another layer. The way the fluorescence distributes across the cell nucleus tells the clinician something about which autoantibodies might be present. A homogeneous pattern suggests one family of antibodies, a speckled pattern another, a centromere pattern yet another. Reading these patterns requires trained eyes (or trained software), and the interpretation itself takes time, especially when patterns overlap or are ambiguous. The technique is labor-intensive and subject to variability from the skill of the reader, the quality of the reagents, and even the microscope bulb being used.

How Much Extra Time to Expect

The exact delay depends on where your blood is being processed. At a hospital-based lab that runs ANA testing daily, a negative result might be available within one to two business days of the draw. A positive result from the same lab could take an extra day or two while the titration and pattern reading are completed. At reference laboratories that handle samples from multiple clinics, the turnaround can stretch further because samples may be batched and run only on certain days. Positive samples that trigger reflex testing to an extractable nuclear antigen (ENA) panel or a double-stranded DNA antibody test may not have a complete report for five to seven business days total.

If you are waiting and your result seems delayed, that does not necessarily confirm a positive result. Labs batch negatives and positives together in the same run, and workflow bottlenecks, weekends, and shipping delays all affect turnaround. But statistically, the more time passes beyond the lab’s stated turnaround window, the more likely it is that additional testing was triggered by a positive screen.

The Reflex Testing Chain

Many laboratories use a “reflex” or “cascade” approach. The ANA IIF screen is the first gate. If it is negative, the chain ends. If it is positive, the lab automatically proceeds to further testing without the ordering physician needing to place a separate order. This reflex chain can include:

Titer determination: Serial dilutions to quantify how concentrated the antibodies are.
Pattern identification: Characterizing the fluorescence pattern to guide clinical interpretation.
ENA panel: Testing for specific antibodies like anti-Smith, anti-RNP, anti-SSA (Ro), anti-SSB (La), anti-Scl-70, and anti-Jo-1, which point toward specific autoimmune diseases.
Anti-dsDNA antibody: A test more specific to lupus, often ordered reflexively when the ANA pattern is homogeneous.

Each link in the chain adds processing time. The ENA panel alone may use a different testing platform from the IIF, such as an enzyme immunoassay or a multiplex bead assay, and the two platforms do not always run on the same schedule. In some reference labs, the ANA IIF runs daily but the ENA panel runs only twice a week, creating a built-in gap. This is the main reason a positive ANA result can feel like it takes significantly longer: you are not waiting for one test; you are waiting for several.

Does the Testing Method Matter?

The short answer is yes, and labs are increasingly adopting technologies designed to shorten that gap. Newer fully automated IIF systems can screen samples, predict the likely endpoint titer, and reduce the number of dilution wells that need to be processed. One study evaluating such a system found that positive samples screened at a 1:80 dilution could be reflexed to further dilution based on the instrument’s predicted titer, cutting down on unnecessary wells and saving time.

Automated image analysis is another area where turnaround times are shrinking. Software that reads fluorescence images and classifies patterns has shown very good agreement with trained human observers for both positive/negative calls and pattern recognition. This removes one of the slowest bottlenecks in the traditional workflow: the need for a skilled technologist to sit at a microscope and evaluate each positive slide individually.

⁴

Some labs have moved away from IIF entirely for the initial screen, using solid-phase assays such as chemiluminescent immunoassays (CLIA) or enzyme-linked immunosorbent assays (ELISA) instead. These platforms are highly automated, can process large numbers of samples in random-access mode (meaning they do not need to wait for a full batch), and produce quantitative results without the manual dilution steps IIF requires. Chemiluminescent assays in particular have been noted for their wide dynamic range, high sensitivity, and ability to reduce turnaround time substantially compared to traditional methods.

⁵

The trade-off is that IIF remains the gold-standard screening method recommended by most international guidelines, partly because it can detect a broader range of autoantibodies than solid-phase assays. So even when a lab uses CLIA or ELISA for rapid screening, a positive result may still get reflexed to IIF for pattern identification, adding time right back into the process.

What a Delay Does and Does Not Tell You

It is tempting to interpret a slow result as a sign that something is wrong. That instinct is partially correct: as described, positives genuinely do take longer because of the additional laboratory steps. But the delay itself carries no diagnostic weight. A positive ANA is not a diagnosis. Somewhere around one in seven to one in five healthy people will test positive for ANAs at low titers, depending on the screening dilution and the population studied. Most of those people do not have and will not develop an autoimmune disease.

Conversely, a fast negative result is not always a clean bill of health. Certain autoimmune conditions can present with a negative ANA, particularly early in the disease course or in conditions where the relevant antibodies are not directed at nuclear antigens. Your doctor ordered the test as one piece of a larger puzzle, and the speed of the result is not part of that puzzle’s clinical meaning.

When Your Doctor Orders a Repeat Test

If you have had an ANA test before and your doctor orders another, the same timing dynamic applies: a positive retest triggers reflex steps and takes longer. But it is worth knowing how stable ANA results tend to be over time. A large retrospective analysis of repeated ANA tests found that results stayed the same in about two-thirds of cases. When results did change, the most common shift was from positive to negative, which happened roughly 9% of the time. Moderately and strongly positive results were particularly stable: samples at titers of 1:320 to 1:640 changed direction less than 2% of the time, and strongly positive samples at 1:1280 or higher never seroconverted in the study period.

⁶

The practical implication is that retesting a strongly positive ANA to “see if it changed” is unlikely to yield different information, and it will take just as long the second time because the same reflex chain kicks in again. If your prior result was strongly positive and your symptoms have not changed, a repeat test is usually not adding clinical value. On the other hand, if you tested weakly positive with no clear diagnosis, a repeat after a year or more might occasionally show a different picture, though even then two-thirds of results hold steady.

Factors That Slow Down Any ANA Result, Positive or Negative

Some delays have nothing to do with whether your sample is positive. Understanding these can help you set realistic expectations and avoid reading too much into timing alone.

Batch scheduling: Many labs do not run ANA tests continuously. Samples may sit in a queue until the next scheduled batch, which could be the following day or, at smaller facilities, once or twice a week.
Send-out testing: If your clinic does not have an in-house immunology lab, your sample is shipped to a reference lab. Transit time alone can add one to three days.
Manual review requirements: Even with automation, many labs still require a trained technologist to confirm flagged results before release, especially borderline or unusual patterns. Staffing shortages or high volumes can create backlogs.
Specimen issues: Hemolyzed or lipemic samples (those that are visibly pink or milky) can interfere with fluorescence readings and may need to be recollected, restarting the clock entirely.

If you want a clearer timeline, ask your clinic which lab processes the sample and whether the ANA is run in-house or sent out. Send-out tests almost always take longer regardless of the result.

Why the Lab Does Not Just Call You If It Is Positive

People sometimes expect that a positive result, like a critical lab value, would prompt an immediate phone call. But an ANA does not work like a dangerously high potassium level or a critically low hemoglobin. A positive ANA is, in itself, not an emergency finding. The result needs to be interpreted in the context of your symptoms, your other lab work, and your medical history. Labs release the result to the ordering provider, who then integrates it with the clinical picture before contacting you. This interpretive step adds perceived delay on top of the actual laboratory delay, especially if your doctor wants to wait for the full reflex panel before calling.

If anxiety about the wait is getting to you, it is reasonable to call your provider’s office and ask whether the ANA screen itself has resulted, even if the reflex tests have not. Some electronic patient portals release individual test components as they finalize, so you may see your ANA IIF titer and pattern before the ENA panel posts. Seeing partial results without the full clinical discussion can be confusing, though, so keep that trade-off in mind.

How Automation Is Changing the Waiting Game

The gap between negative and positive turnaround times is narrowing, and the reason is primarily automation. Traditional IIF-based ANA testing had a built-in asymmetry: a negative sample needed one read, while a positive sample needed multiple dilutions, pattern interpretation, and sometimes a second reader for confirmation. Each of those steps required human hands and human eyes. Modern automated systems compress several of those steps. Instruments that both prepare the slides and read them digitally can predict the likely endpoint titer from the initial screening well, skipping intermediate dilution steps that would have been done manually. Pattern classification software runs in seconds rather than the minutes a technologist might spend squinting through a microscope. The result is that while positive samples still require more processing than negative ones, the margin has shrunk substantially in labs that have adopted full automation.

Labs using chemiluminescent or multiplex bead platforms for the entire antibody workup, rather than cascading from IIF to a separate ENA platform, can sometimes deliver a full panel of results from a single run. Because these systems quantify multiple antibodies simultaneously, the concept of a “reflex” test becomes less relevant: the instrument tests for everything in parallel, and both the ANA equivalent and the specific antibody results come back at roughly the same time. For patients at these labs, the positive-versus-negative timing gap may be almost nonexistent. The catch, as always, is that not every lab has adopted these newer platforms, and many clinical guidelines still prefer IIF as the initial screen. The technology is ahead of the standard of care in some respects, which means the experience of waiting still varies widely depending on where your blood ends up.

⁵

1
PubMed Central. Assessment of ideal serum dilution for screening of antinuclear antibodies by an indirect immunofluorescence method in diagnosis of autoimmune disorders
2
Scientific Scholar (Journal of Skin and Sexually Transmitted Diseases). Anti-nuclear antibodies: A practical approach to testing and interpretation
3
Frontiers in Immunology. Evaluation of a Fully Automated Antinuclear Antibody Indirect Immunofluorescence Assay in Routine Use
4
PubMed Central. Performance analysis of automated evaluation of antinuclear antibody indirect immunofluorescent tests in a routine setting
5
PubMed Central. Chemiluminescent immunoassay technology: what does it change in autoantibody detection?
6
Cureus. Frequency of Repeating Antinuclear Antibody Testing: When Less Is More